adcom vote baricitinib
baricitinib drug partner lilli receiv mix posit vote
lower dose neg vote higher dose baricitinib
rheumatoid arthriti believ commentari mix vote neg
baricitinib uptak approv pdufa earli june could knock
effect eu consequ lower pt
expect baricitinib estim reduc believ stock
attract price current level reiter buy
adcom vote favor panel vote
risk benefit profil mg dose baricitinib adequ support approv
rheumatoid arthriti adult patient moder sever activ
rheumatoid arthriti inadequ respons intoler
methotrex howev panel vote risk benefit data
support dose profil discuss highlight clinician concern
safeti drug suggest baricitinib could use
biolog option exhaust view result increment
neg rais likelihood success baricitinib
 get step closer potenti approv
dose lower penetr reflect clinician
caution conserv also lower eu estim account
possibl knock effect uncertain clinic futur baricitinib
unit state note fda bound result
adcom vote await outcom pdufa
addit focus lilli buy john bori earn call
tomorrow april addit color baricitinib repres
model chang adcom rais likelihood approv
reduc penetr combin
tweak pt move
efficaci vote posit safeti controversi panel
larg agreement efficaci baricitinib doctor vote
mg dose effect mg dose exhibit
safeti vote mix mg dose panel vote
safeti data adequ approv baricitinib mg dose panel
vote data adequ approv mg dose
tr target
exhibit baricitinib efficaci vote posit safeti controversi
strh compani report
catalyst focu molecul pivot phase trial result jakafi
steroid refractori agvhd earli june olumi pdufa date data gitr
molecul next month
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt jakafi
mf pv gvhd olumi epacadostat melanoma
solid tumor cash/technolog bull/bear case model yield pt risk includ
failur epacadostat competit impact jakafi olumi uptak
page
data catalyst next month highlight
page
candidatetargettim mileston settingpartnerepacadostat durvalumab data solid tumorsio data pair biopsi trial multipl tumor typesepacadostat keytruda updatesolid tumorsepacadostat opdivo updatesolid datasolid datasolid tumorsruxolitnib phase resultssteroid refrectori initi pivot programpsoriat arthritis junepdufarheumatoid arthritis glioblastoma liver cancer incyt corpor
page
 epacadostat- jakavi olumiant- mileston revenues- adjust sale probabl success weight weight epacadostat- technolog corpor
page
page
quarterli sale royaltiesjakafi jakafi gvhd/transplant- iclusig cml- product olumi ra us- ra row- fair valu acquisit incom incom incom ep product ep inc stock share outstand corpor
page
annual jakafi gvhd/transplant- epacadostat melanoma- epacadostat solid tumor- iclusig cml- total product total fair valu acquisit incom interest incom incom ep inc stock share outstand corpor
commerci stage biotech compani believ gener signific cash flow
two partner asset develop deep pipelin oncolog asset incyt commerci asset jakafi
could see upsid addit indic fulli partner arthriti molecul olumi
launch would help fund well posit immuno-oncolog target
jakafi above-p biotech growth addit upsid new indic jakafi rapidli
grow drug myelofibrosi polycythemia vera project revenu
jakafi drug show durabl effect clinic benefit importantli jakafi
also shown encourag clinic benefit graft vs host diseas project peak
sale additoin valu come baricitinib non-oncolog rheumatoid arthriti ra focus cash
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt jakafi mf pv gvhd
olumi epacadostat melanoma solid tumor cash/
technolog bull/bear case model yield pt risk includ failur epacadostat
competit impact jakafi olumi uptak
compani mention note
compani buy john bori
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
